title: Vigabatrin in refractory childhood epilepsy. The Brazilian Multicenter Study.
abstract: Children, 47, with various types of severe drug-resistant epilepsy were entered into a prospective, add-on, open trial with vigabatrin. Patients with West syndrome and idiopathic generalized epilepsies were excluded. Seven children had the drug withdrawn, five because of increase in seizure frequency and two because of adverse effects. Drug efficacy, measured according to seizure type, showed a 100% decrease in seizure frequency in 18.6% of partial seizures and 17.3% of the generalized seizures. There was a higher than 50% decrease in 39.5% of partial and 60.8% of generalized seizures, and less than 50% decrease or increase in seizure frequency in 41.8% and 21.8% of partial and generalized seizures, respectively. Vigabatrin mean dosage during phase 3 was 63.6 mg/kg per day (S.D. = 30.5), ranging from 19.3 to 110.5 mg/kg per day. Parametric statistical analysis (Student's t-test) of seizure frequency between phases 1 and 3 showed a significant decrease in seizure frequency for partial (P = 0.022), and generalized seizures (P < 0.0001). Drug-related adverse effects were observed in 18/47 cases (38.3%), consisting mainly of irritability, hyperactivity, dizziness, somnolence and gastrointestinal symptoms.
authors.affiliation: Serviço de Neurologia Infantil, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brazil.
authors.forename: J L
authors.initials: JL
authors.lastname: Gherpelli
authors.forename: M M
authors.initials: MM
authors.lastname: Guerreiro
authors.forename: J C
authors.initials: JC
authors.lastname: da Costa
authors.forename: N T
authors.initials: NT
authors.lastname: Rotta
authors.forename: M L
authors.initials: ML
authors.lastname: Manreza
authors.forename: U C
authors.initials: UC
authors.lastname: Reed
authors.forename: A
authors.initials: A
authors.lastname: Diament
authors.forename: E A
authors.initials: EA
authors.lastname: Silva
authors.forename: C A
authors.initials: CA
authors.lastname: Guerreiro
authors.forename: M L
authors.initials: ML
authors.lastname: Nunes
authors.forename: A
authors.initials: A
authors.lastname: Palmini
authors.forename: L
authors.initials: L
authors.lastname: Vega-Gutiérrez
authors.forename: J
authors.initials: J
authors.lastname: Vizioli
authors.forename: F
authors.initials: F
authors.lastname: Pedroso
authors.forename: M A
authors.initials: MA
authors.lastname: Chisté
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D011446:Prospective Studies; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin